Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Patients on Stable Dialysis

Next Previous
Trial Profile

A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Patients on Stable Dialysis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roxadustat (Primary) ; Darbepoetin alfa; Darbepoetin alfa; Epoetin alfa; Epoetin alfa
  • Indications Anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms Pyrenees
  • Sponsors Astellas Pharma BV

Most Recent Events

  • 07 Jan 2026 According to FibroGen media release, FibroGen is now called as Kyntra Bio.
  • 19 Sep 2021 Results assessing the efficacy and safety of roxadustat in patients with end-stage kidney disease on dialysis for at least 4 months assessing published in the Advances in Therapy
  • 14 Sep 2021 Results of pooled analysis assessing efficacy and safety of roxadustat in the largest possible global population of DD patients with anemia of CKD from four phase 3 trials (PYRENEES, HIMALAYAS, SIERRAS and ROCKIES) published in the Advances in Therapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top